Kwality Pharmaceuticals Limited (NSE:KPL)

Market Cap	38.65B +296.3%
Revenue (ttm)	5.54B +37.9%
Net Income	810.45M +86.7%
EPS	78.10 +86.8%
Shares Out	n/a
PE Ratio	47.69
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,326
Open	3,773.00
Previous Close	3,752.80
Day's Range	3,705.00 - 3,827.70
52-Week Range	1,561.00 - 3,949.00
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2026

About Kwality Pharmaceuticals

Kwality Pharmaceuticals Limited, together with its subsidiary, manufactures finished pharmaceutical formulations in India and internationally. The company offers its products in various dosage forms, including capsules, eye and ear drops, ointments and creams, pouches and sachets, sanitizers, tablets, suppositories, injectable vials and ampoules, liquid orals, lyophilized products, syrups, and various other categories, such as general, beta-lactam, cephalosporins, oncology, biologics, and hormones and specialty injectables. It also provides int...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1983
• Employees: 1,137
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: KPL

Financial Performance

In fiscal year 2026, Kwality Pharmaceuticals's revenue was 5.03 billion, an increase of 35.90% compared to the previous year's 3.70 billion. Earnings were 673.46 million, an increase of 69.02%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 24, 2026

Data Sources Report a data error